Latent tuberculosis infection in patients with rheumatic diseases

Latent tuberculosis infection in patients with rheumatic diseases

ABSTRACT Most people infected by Mycobacterium tuberculosis (Mtb) do not have any signs or disease symptoms, a condition known as latent tuberculosis infection (LTBI). The introduction of biological agents, mainly tumor necrosis factor (TNF) inhibitors, for the treatment of immune-mediated diseases such as Rheumatoid Arthritis (RA) and other rheumatic diseases, increased the risk of reactivation of LTBI, leading to development of active TB. Thus, this review will approach the aspects related to LTBI in patients with rheumatologic diseases, especially those using iTNF drugs. For this purpose it will be considered the definition and prevalence of LTBI, mechanisms associated with diseases and medications in use, criteria for screening, diagnosis and treatment. Considering that reactivation of LTBI accounts for a large proportion of the incidence of active TB, adequate diagnosis and treatment are crucial, especially in high-risk groups such as patients with rheumatologic diseases.

Saved in:
Bibliographic Details
Main Authors: Anton,Camila, Machado,Felipe Dominguez, Ramirez,Jorge Mario Ahumada, Bernardi,Rafaela Manzoni, Palominos,Penélope Esther, Brenol,Claiton Viegas, Mello,Fernanda Carvalho de Queiroz, Silva,Denise Rossato
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Pneumologia e Tisiologia 2019
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132019000200502
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Most people infected by Mycobacterium tuberculosis (Mtb) do not have any signs or disease symptoms, a condition known as latent tuberculosis infection (LTBI). The introduction of biological agents, mainly tumor necrosis factor (TNF) inhibitors, for the treatment of immune-mediated diseases such as Rheumatoid Arthritis (RA) and other rheumatic diseases, increased the risk of reactivation of LTBI, leading to development of active TB. Thus, this review will approach the aspects related to LTBI in patients with rheumatologic diseases, especially those using iTNF drugs. For this purpose it will be considered the definition and prevalence of LTBI, mechanisms associated with diseases and medications in use, criteria for screening, diagnosis and treatment. Considering that reactivation of LTBI accounts for a large proportion of the incidence of active TB, adequate diagnosis and treatment are crucial, especially in high-risk groups such as patients with rheumatologic diseases.

Similar Items